IP
Ian Peikon
Venture Partner at Lux Capital
Seattle, Washington
Overview
Ian Peikon is the Co-Founder & Co-Chief Executive Officer of Cajal Neuroscience, having successfully led the company through its Series A funding round. With a PhD from Cold Spring Harbor Laboratory and experience as a Venture Partner at Lux Capital, Ian has established himself as a prominent figure in the biotech industry, specializing in molecular biology and neuroscience.
Work Experience
Co-Founder & Co-Chief Executive Officer
2020 - Current
Advisory Board Member
2024
Board Member
2022
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Raised $165,000,000.00 from CRV, RA Capital Management, Pappas Capital, DCVC Bio, SoftBank Vision Fund, Pivotal bioVenture Partners, M Ventures, Surveyor Capital, Lux Capital and Neotribe Ventures.
Venture Partner
2019
Lux Capital is an investment firm that invests in counter-conventional, seed-stage science and technology ventures.
Co-Founder & SAB Member
2018 - 2022
non-viral gene therapy delivery systems - acquired by Aera Therapeutics
Co-Founder & Director, Platform Biology & Technology
2015 - 2019
I was part of the founding team of Kallyope and led the platform for new target discovery.
Kallyope uses the science of gut-brain biology to create medicines that transform human health.
Raised $487,200,000.00 from Bill & Melinda Gates Foundation.